PharmaSGP Holding SE
XETRA:PSG
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
19.2
26
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
PharmaSGP Holding SE
PharmaSGP Holding SE
Cash & Cash Equivalents
PharmaSGP Holding SE
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PharmaSGP Holding SE
XETRA:PSG
|
Cash & Cash Equivalents
€40.8m
|
CAGR 3-Years
72%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
Cash & Cash Equivalents
$45m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bayer AG
XETRA:BAYN
|
Cash & Cash Equivalents
€4.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
11%
|
|
|
Merck KGaA
XETRA:MRK
|
Cash & Cash Equivalents
€3.2B
|
CAGR 3-Years
28%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
9%
|
|
|
MPH Health Care AG
XETRA:93M1
|
Cash & Cash Equivalents
€4.6m
|
CAGR 3-Years
131%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
Dermapharm Holding SE
XETRA:DMP
|
Cash & Cash Equivalents
€118.6m
|
CAGR 3-Years
0%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
PharmaSGP Holding SE
Glance View
PharmaSGP Holding SE engages in the sale and marketing of non-prescription drugs, chemical-free over-the-counter painkillers, as well as herbal medicines. The company is headquartered in Graefelfing, Bayern. The company went IPO on 2020-06-19. The firm produces and develops non-chemical and over-the-counter drugs and other healthcare products.
See Also
What is PharmaSGP Holding SE's Cash & Cash Equivalents?
Cash & Cash Equivalents
40.8m
EUR
Based on the financial report for Dec 31, 2023, PharmaSGP Holding SE's Cash & Cash Equivalents amounts to 40.8m EUR.
What is PharmaSGP Holding SE's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-12%
Over the last year, the Cash & Cash Equivalents growth was 25%. The average annual Cash & Cash Equivalents growth rates for PharmaSGP Holding SE have been 72% over the past three years , -12% over the past five years .
You don't have any saved screeners yet
